122 related articles for article (PubMed ID: 8349432)
1. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Weiss GR; Brown TD; Kuhn JG; Von Hoff DD; Earhart RH; Adams WJ; Brewer JE; Hosley JD; Kasunic DA
Invest New Drugs; 1993 Feb; 11(1):17-27. PubMed ID: 8349432
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study.
Taylor SA; Blumenstein BA; Stephens RL; Crawford ED; Pistone B; Hill JB
Invest New Drugs; 1994; 12(1):67-70. PubMed ID: 7960610
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.
Mazurek C; Dutcher JP; Schwartz EL; Garl S; Benson L; Wiernik PH
Invest New Drugs; 1993 Nov; 11(4):313-22. PubMed ID: 8157473
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of intravenous menogaril in patients with advanced breast cancer.
Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of oral menogaril administered on a once weekly schedule.
Stewart DJ; Verma S; Maroun JA; Robillard L; Earhart RH
Invest New Drugs; 1990 Feb; 8(1):43-52. PubMed ID: 2140564
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
17. Potential role of oral anthracyclines in older patients with cancer.
Lasota WS; de Valeriola DL; Piccart MJ
Drugs Aging; 1994 May; 4(5):392-402. PubMed ID: 8043941
[TBL] [Abstract][Full Text] [Related]
18. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors.
Piergies AA; Benson AB
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):63-9. PubMed ID: 7757312
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults.
Stewart DJ; Hugenholtz H; DaSilva VF; Benoit BG; Richard MT; Verma S; Earhart R; Robillard L
J Neurooncol; 1992 Jun; 13(2):183-8. PubMed ID: 1331346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
